- Report
- May 2025
- 320 Pages
Global
From €5271EUR$5,950USD£4,567GBP
- Report
- November 2024
- 150 Pages
Global
From €5271EUR$5,950USD£4,567GBP
- Report
- July 2025
- 192 Pages
Global
From €5182EUR$5,850USD£4,490GBP
- Report
- October 2024
- 210 Pages
Global
From €2215EUR$2,500USD£1,919GBP
- Report
- January 2025
- 200 Pages
Global
From €3977EUR$4,490USD£3,446GBP
- Report
- July 2025
- 371 Pages
Global
From €5182EUR$5,850USD£4,490GBP
- Report
- July 2025
- 194 Pages
Global
From €5182EUR$5,850USD£4,490GBP
- Report
- December 2024
- 200 Pages
Global
From €3322EUR$3,750USD£2,878GBP
- Report
- March 2025
- 100 Pages
Global
From €3500EUR$4,233USD£3,139GBP
- Report
- December 2021
- 346 Pages
Global
From €3322EUR$3,750USD£2,878GBP
- Report
- May 2022
- 228 Pages
Global
From €2325EUR$2,625USD£2,015GBP
€4651EUR$5,250USD£4,030GBP
- Report
- August 2024
- 80 Pages
Japan
From €2635EUR$2,975USD£2,283GBP
€3100EUR$3,500USD£2,686GBP
- Report
- February 2024
- 113 Pages
Global
From €4208EUR$4,750USD£3,646GBP
- Report
- April 2023
- 110 Pages
Global
From €4208EUR$4,750USD£3,646GBP
- Report
- August 2022
- 116 Pages
Global
From €4208EUR$4,750USD£3,646GBP
- Book
- April 2024
- 448 Pages
- Book
- April 2023
- 176 Pages
- Book
- May 2021
- 512 Pages
- Book
- January 2016
- 952 Pages

Sickle Cell Disease (SCD) is a group of inherited red blood cell disorders caused by a genetic mutation in the hemoglobin gene. It is characterized by red blood cells that are shaped like a sickle, or crescent, which can cause blockages in small blood vessels. This can lead to a wide range of symptoms, including anemia, pain, organ damage, and stroke. SCD is most common among people of African, Mediterranean, and Indian descent, and is estimated to affect millions of people worldwide.
Treatment for SCD is focused on managing symptoms and preventing complications. This includes medications to reduce pain, antibiotics to prevent infections, and blood transfusions to reduce the risk of stroke. In some cases, stem cell transplants may be used to replace the defective hemoglobin gene.
The SCD market is a subset of the larger hematology market, which includes treatments for a variety of blood disorders. Companies in this market include Novartis, GlaxoSmithKline, Pfizer, and Sanofi. Other companies, such as Celgene and Gilead Sciences, are also involved in the development of treatments for SCD. Show Less Read more